Most cited papers from Arizona Oncology

Arizona Oncology

What are the most cited papers from Arizona Oncology?

The most cited paper from Arizona Oncology is "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)" (Daniel J. Klionsky et al., 2016), with 6,023 citations. Next come "The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma" (3,883) and "Pancreatic cancer" (2,586).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 291 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors	2 Jan 2016	6,023
2	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma Andreas Rosenwald et al. · New England Journal of Medicine Open access	20 Jun 2002	3,883
3	Pancreatic cancer Jonathan D. Mizrahi, Rishi Surana, Juan W. Valle et al. · The Lancet	Jun 2020	2,586
4	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza et al. · New England Journal of Medicine Open access	8 Oct 2016	2,495
5	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer David D.L. Bowtell et al. · Nature reviews. Cancer ReviewOpen access	23 Oct 2015	1,444
6	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma Jan C. Buckner et al. · New England Journal of Medicine Open access	6 Apr 2016	1,071
7	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival Daniel F.C. Hayes, Massimo Cristofanilli, George Thomas Budd et al. · Clinical Cancer Research	15 Jul 2006	1,051
8	Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines Jason S. Damiano, Anne E. Cress, Lori Hazlehurst et al. · Blood Open access	Mar 1999	872
9	Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza et al. · New England Journal of Medicine Open access	27 Mar 2023	865
10	Lack of Effect of a High-Fiber Cereal Supplement on the Recurrence of Colorectal Adenomas David Samuel Alberts, Marı́a Elena Martı́nez, Denise J. Roe et al. · New England Journal of Medicine Open access	20 Apr 2000	828
11	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari et al. · The Lancet Open access	27 Jul 2017	697
12	Thrombocytopenia caused by the development of antibodies to thrombopoietin Junzhi Li, Chun Yang, Yuping Xia et al. · Blood	Dec 2001	688
13	Gamma knife radiosurgery for trigeminal neuralgia: the initial experience of the Barrow Neurological Institute Leland Rogers, Andrew G. Shetter, Jeffrey A. Fiedler et al. · International Journal of Radiation OncologyBiologyPhysics	Jul 2000	636
14	American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer Subir Nag, DAVID C. BEYER, Jay L. Friedland et al. · International Journal of Radiation OncologyBiologyPhysics	Jul 1999	623
15	Tumor-stroma interactions in pancreatic ductal adenocarcinoma Daruka Mahadevan, Daniel D. Von Hoff · Molecular Cancer Therapeutics Open access	Apr 2007	609
16	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol Luís Souhami, Wendy F. Seiferheld, David G Brachman et al. · International Journal of Radiation OncologyBiologyPhysics	5 Oct 2004	567
17	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Kathleen N. Moore, Angeles Alvarez Secord, Melissa Ann Geller et al. · The Lancet Oncology	Apr 2019	545
18	Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Anna J. Duffield‐Lillico, Mary E. Reid, Bruce W. Turnbull et al. · PubMed	Jul 2002	543
19	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Vicky Makker, Matthew Hiram Taylor, Carol A Aghajanian et al. · Journal of Clinical Oncology Open access	13 Mar 2020	531
20	Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial Anna J. Duffield‐Lillico, B.L. Dalkin, Marvin Ellsworth Reid et al. · British Journal of Urology	16 Apr 2003	516
21	G-quadruplex DNA: a potential target for anti-cancer drug design Haiyong Han, Laurence H. Hurley · Trends in Pharmacological Sciences Review	Apr 2000	491
22	Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy Patrick A. Kupelian, Twyla R. Willoughby, Arul Mahadevan et al. · International Journal of Radiation OncologyBiologyPhysics	22 Dec 2006	489
23	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial Frank A. Vicini et al. · The Lancet Open access	Dec 2019	488
24	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology Open access	26 Mar 2019	482
25	Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Kathleen N. Moore et al. · New England Journal of Medicine Open access	6 Dec 2023	478
26	Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation Michael J. Zeléfsky, Deborah Ann Kuban, Larry B. Levy et al. · International Journal of Radiation OncologyBiologyPhysics	3 Nov 2006	468
27	Primary Bioassay of Human Myeloma Stem Cells Anne W. Hamburger, Sydney E. Salmon · Journal of Clinical Investigation Open access	Oct 1977	468
28	Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions Yong Wen Qin, Laurence H. Hurley · Biochimie Open access	19 Mar 2008	454
29	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy Neil F. Mariados et al. · International Journal of Radiation OncologyBiologyPhysics Open access	23 Apr 2015	436
30	Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Alan N. Gordon, Margaret Eleanor Tonda, Steven H. Sun et al. · Gynecologic Oncology	21 Sep 2004	433
31	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) Kathleen N. Moore et al. · Journal of Clinical Oncology Open access	23 Apr 2021	428
32	Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study Éric Pujade-Lauraine et al. · The Lancet Oncology Open access	15 Jun 2021	426
33	Polymorphism of human telomeric quadruplex structures Jixun Dai, Megan Carver, Danzhou Yang · Biochimie Open access	10 Mar 2008	422
34	Systems Thinking to Improve the Public's Health Scott James Leischow, Allan Best, William M. K. Trochim et al. · American Journal of Preventive Medicine Open access	10 Jul 2008	419
35	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert Louis Coleman et al. · The Lancet Oncology	9 Apr 2021	410
36	Uterine Microbiota: Residents, Tourists, or Invaders? James M. Baker, Dana Meredith Chase, Melissa M. Herbst‐Kralovetz · Frontiers in Immunology Open access	Mar 2018	409
37	Non‐erosive reflux disease (NERD) — acid reflux and symptom patterns Stephanie D. Martinez, Isaac B. Malagon, H S Garewal et al. · Alimentary Pharmacology & Therapeutics Open access	Feb 2003	396
38	The Dynamic Character of the G-Quadruplex Element in the c-MYC Promoter and Modification by TMPyP4 Jeyaprakashnarayanan Seenisamy, Evonne M. Rezler, Tiffanie J. Powell et al. · Journal of the American Chemical Society	22 Jun 2004	387
39	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Daniel Allan Hamstra et al. · International Journal of Radiation OncologyBiologyPhysics Open access	23 Dec 2016	384
40	Solution Structure of a 2:1 Quindoline–c-MYC G-Quadruplex: Insights into G-Quadruplex-Interactive Small Molecule Drug Design Jixun Dai, Megan Carver, Laurence H. Hurley et al. · Journal of the American Chemical Society Open access	3 Oct 2011	381
41	Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy Martin E. Keisch, Frank A. Vicini, Robert R. Kuske et al. · International Journal of Radiation OncologyBiologyPhysics	17 Jan 2003	379
42	Patient‐reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy Linda S. Elting, Dorothy M. K. Keefe, Stephen T. Sonis et al. · Cancer Open access	30 Oct 2008	373
43	The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Cory L. Grand, Haiyong Han, Rubén M. Muñoz et al. · PubMed	Jun 2002	370
44	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline Alexi A. Wright, Kari Bohlke, Deborah Kay Armstrong et al. · Gynecologic Oncology Open access	10 Aug 2016	368
45	Glypicans: proteoglycans with a surprise Jorge Filmus, Scott B. Selleck · Journal of Clinical Investigation Open access	15 Aug 2001	364
46	Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial Ajay Pabby, Robert E. Schoen, Joel L. Weissfeld et al. · Gastrointestinal Endoscopy	Mar 2005	353
47	Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes William T. Bellamy, Lynne C. Richter, Davuud Sirjani et al. · Blood	Mar 2001	342
48	Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial Edward G. Shaw, Brian A. Berkey, Stephen William Coons et al. · Journal of neurosurgery Open access	31 Oct 2008	333
49	Tumorigenicity in Human Melanoma Cell Lines Controlled by Introduction of Human Chromosome 6 Jeffrey M. Trent, Eric J. Stanbridge, Heyoung L. McBride et al. · Science	2 Feb 1990	331
50	Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling Zehra Esra Ilhan, Paweł Łaniewski, Natalie Thomas et al. · EBioMedicine Open access	24 Apr 2019	326

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.